| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Scheeren Joseph serves as a Director at BRNS. Across recent SEC filings that breaks down to 3 buys and 0 sells. Those positions are worth an estimated $56K at current prices.
Historically, Scheeren Joseph's trades have earned a below-average insider score of 29/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -53.0%.
The biggest single holding is BRNS (~$56K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 23,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 10,000 | $2.44 | $24,400.00 | +76.9% | +39.2% | -40.1% | |
| Apr 1, 2022 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 10,000 | $5.09 | $50,900.00 | +333.3% | -14.3% | -56.8% | |
| May 4, 2021 | BRNS Barinthus Biotherapeutics Plc. | Director | Buy | 3,000 | $17.00 | $51,000.00 | New | +14.1% | -62.1% |